Quantum Biopharma ( (TSE:QNTM) ) has provided an update.
Quantum BioPharma Ltd. has announced the grant of 60,000 restricted share units under its equity incentive plan, subject to specific vesting criteria and a hold period as per Canadian Securities Exchange policies. Additionally, the company has approved a debt settlement with arm’s length parties by issuing Class B Shares, which will also be subject to a hold period. These updates are part of Quantum BioPharma’s ongoing efforts to strengthen its financial position and operational capabilities, potentially impacting its market standing and stakeholder interests.
More about Quantum Biopharma
Quantum BioPharma Ltd. is a biopharmaceutical company focused on developing innovative biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The company is advancing drug candidates at various development stages and has a subsidiary, Lucid Psycheceuticals Inc., working on a compound for multiple sclerosis. Quantum BioPharma also has a strategic investment portfolio through FSD Strategic Investments Inc.
YTD Price Performance: 54.41%
Average Trading Volume: 2,821,255
Technical Sentiment Signal: Buy
Current Market Cap: $14.37M
See more insights into QNTM stock on TipRanks’ Stock Analysis page.